Cyclo Therapeutics is a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. Co.'s primary drug candidate, Trappsol® Cyclo (hydroxypropyl beta cyclodextrin), is used as a treatment for Niemann-Pick Type C disease (NPC). NPC is a cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. Co. is also exploring the use of cyclodextrins in the treatment of Alzheimer's disease. Co. sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The CYTH stock yearly return is shown above.
The yearly return on the CYTH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CYTH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|